icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
LQjPEFNnyHMAr9U8
Listen
